Dr. Wucherpfennig has provided scientific and administrative leadership for this PPG since 1999, and this effort has been productive as evidenced by the large number of collaborative publications, many of which have been in high-impact journals. He will continue to closely interact with all members ofthe team to foster collaboration and identify new scientific opportunities. Dr. Wucherpfennig will organize regular formal scientific meetings at which recent progress will be presented and new opportunities for collaboration will be discussed. All project leaders work in the Boston area, Drs. Wucherpfennig, Turtey and Kuchroo on the Harvard Medical School (HMS) campus, and Dr. Love at the Koch Institute of MIT. Drs. Turley and Wucherpfennig are neighbors at the Dana-Farber Cancer Institute, and Drs. Kuchroo, Turtey and Wucherpfennig frequently meet at seminars and as part of the Program for Immunology at HMS. Drs. Kuchroo and Wucherpfennig also jointly teach an annual quarter course on Autoimmunity'for graduate students (since 1999). These frequent interactions foster dialogue and collaboration. In addition. Dr. Wucherpfennig will organize annual meetings with the Scientific Advisory Board (SAB) at which each project leader will present recent progress and discuss directions for the coming year. All members of our SAB work at HMS, and we will therefore also have many opportunities to consult them on an informal basis. Dr. Wucherpfennig will also continue to be in charge of all administrative aspects and will be assisted by this administrator and Dana-Farber grants and financial management specialists.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI045757-16
Application #
8705348
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Urso, Katia; Alvarez, David; Cremasco, Viviana et al. (2016) IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. JCI Insight 1:
Adams, Jarrett J; Narayanan, Samanthi; Birnbaum, Michael E et al. (2016) Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity. Nat Immunol 17:87-94
Longbrake, Erin E; Hafler, David A (2016) Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy Grail. JAMA Neurol 73:777-8
Singer, Meromit; Wang, Chao; Cong, Le et al. (2016) A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell 166:1500-1511.e9
Fernandez-Carbonell, Cristina; Vargas-Lowy, David; Musallam, Alexander et al. (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 22:174-84
Cao, Yonghao; Nylander, Alyssa; Ramanan, Sriram et al. (2016) CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 86:1553-6
Axisa, Pierre-Paul; Hafler, David A (2016) Multiple sclerosis: genetics, biomarkers, treatments. Curr Opin Neurol 29:345-53
Lowther, Daniel E; Goods, Brittany A; Lucca, Liliana E et al. (2016) PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 1:
Chastre, Anne; Hafler, David A; O'Connor, Kevin C (2016) Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. N Engl J Med 374:1495-6
Astarita, Jillian L; Cremasco, Viviana; Fu, Jianxin et al. (2015) The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol 16:75-84

Showing the most recent 10 out of 117 publications